Related content

Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors

By Pilotto Sara   Bria Emilio  

Lung Cancer Management, Vol. 2, Iss. 2, 2013-04 ,pp. : 89-92

Future Medicine

Access to resources Recommend Favorite

Is EGF receptor–tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?

By Hayashi Hidetoshi   Nakagawa Kazuhiko  

Lung Cancer Management, Vol. 2, Iss. 6, 2013-12 ,pp. : 441-443

Future Medicine

Access to resources Recommend Favorite

Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer

By Shimizu Katsuhiko   Yukawa Takuro   Hirami Yuji   Okita Riki   Saisho Shinsuke   Maeda Ai   Yasuda Koichiro   Nakata Masao  

Targeted Oncology, Vol. 8, Iss. 4, 2013-12 ,pp. : 237-242

Springer Publishing Company

Access to resources Recommend Favorite

Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

By  

Oncology Reports, Vol. 33, Iss. 1, 2015-01 ,pp. : 391-396

Spandidos Publications

Access to resources Recommend Favorite

The landscape of EGFR pathways and personalized management of non-small-cell lung cancer

By Cheng Liang   Zhang Shaobo   Alexander Riley   Yao Yongxue   MacLennan Gregory T   Pan Chong-xian   Huang Jiaoti   Wang Mingsheng   Montironi Rodolfo   Lopez-Beltran Antonio  

Future Oncology, Vol. 7, Iss. 4, 2011-04 ,pp. : 519-541

Future Medicine

Access to resources Recommend Favorite